News
The Augurex team brings together leading scientific, clinical, technical and commercial expertise to ensure that our research translates into advanced diagnostics for improved patient outcomes.
Augurex Life Sciences and Quest Diagnostics Collaborate to Improve Rheumatoid Arthritis Diagnosis and Management
Quest to introduce lab-developed test based on Augurex 14-3-3η (eta) biomarker to U.S. physicians later this month Vancouver, Canada – November 15, 2024 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that it...
Augurex and New Day Diagnostics Announce Launch of Anti-14-3-3eta Multiplex Analyte Specific Reagents; Enabling a First-In-Class Diagnostic Test for Axial Spondyloarthritis
Augurex launches Anti-14-3-3eta Multiplex Analyte Specific Reagents (ASRs), supporting the development of a first-in-class diagnostic test for axial spondyloarthritis (axSpA) by New Day Diagnostics. The new laboratory developed test, which uses Anti-14-3-3eta...
Augurex to Present Axial Spondyloarthritis Data and Exhibit at ACR Convergence 2024 in Washington, DC
Augurex will present new research on 14-3-3η auto-antibodies as a diagnostic marker for axial spondyloarthritis. Augurex will be exhibiting at booth #2540, showcasing its innovative diagnostic for rheumatoid arthritis and newly launched first-in-class diagnostic test...
Augurex Announces Agreement with ARUP Laboratories to Expand Access to Advanced Rheumatoid Arthritis Diagnosis with the Launch of 14-3-3η (eta) Test
Augurex Life Sciences Corp. announces the launch of the 14-3-3η test by ARUP Laboratories, enhancing the early diagnosis and management of RA.The collaboration between Augurex and ARUP Laboratories highlights a mutual dedication to improving patient outcomes and...
Augurex Achieves MDSAP Certification
Vancouver, BC – August 22, 2024 – Augurex Life Sciences Corp., a leader in biomarker-driven diagnostic solutions for the detection and management of autoimmune diseases, today announced its successful certification under the Medical Device Single Audit Program...
Augurex to Present Research on Novel Diagnostic 14-3-3η Auto-Antibody Marker for Axial Spondyloarthritis at the Spondylo Congress in Ghent
Vancouver, Canada – August 20, 2024 – Augurex Life Sciences Corp. today announced that it will be presenting a scientific poster at the upcoming Spondylo Congress, taking place in Ghent, Belgium, from September 5th to 7th, 2024.Augurex’s poster, titled "Novel...
Veteran life sciences executive Mr. Neil Klompas to assume role of President and CEO
Augurex Life Sciences Corp. Names Healthcare Leader Neil Klompas to Succeed Co-Founder Dr. Norma Biln as President and CEO Veteran life sciences executive Mr. Neil Klompas to assume role of President and CEOCo-Founder and outgoing CEO Dr. Norma Biln to helm research...
Augurex to Present Two Posters at ADLM 2024 in Chicago
Vancouver, Canada – July 26, 2024 – Augurex Life Sciences Corp. is pleased to announce that it will be presenting two posters at the upcoming Association for Diagnostic & Laboratory Medicine (ADLM 2024) in Chicago. The event will be held from July 28 to August 1,...
Life Sciences BC Names Augurex 2024 Emerging Company of the Year
VANCOUVER, BC – Life Sciences BC (LSBC) is pleased to announce the recipients of the 26th Annual Life Sciences BC Awards presented by Farris. These awards recognize the exceptional achievements of individuals, companies, and organizations across British Columbia’s...
Augurex Life Sciences and Quest Diagnostics Collaborate to Improve Rheumatoid Arthritis Diagnosis and Management
Quest to introduce lab-developed test based on Augurex 14-3-3η (eta) biomarker to U.S. physicians later this month Vancouver, Canada – November 15, 2024 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that it...
Augurex and New Day Diagnostics Announce Launch of Anti-14-3-3eta Multiplex Analyte Specific Reagents; Enabling a First-In-Class Diagnostic Test for Axial Spondyloarthritis
Augurex launches Anti-14-3-3eta Multiplex Analyte Specific Reagents (ASRs), supporting the development of a first-in-class diagnostic test for axial spondyloarthritis (axSpA) by New Day Diagnostics. The new laboratory developed test, which uses Anti-14-3-3eta...
Augurex Announces Agreement with ARUP Laboratories to Expand Access to Advanced Rheumatoid Arthritis Diagnosis with the Launch of 14-3-3η (eta) Test
Augurex Life Sciences Corp. announces the launch of the 14-3-3η test by ARUP Laboratories, enhancing the early diagnosis and management of RA.The collaboration between Augurex and ARUP Laboratories highlights a mutual dedication to improving patient outcomes and...
Augurex Achieves MDSAP Certification
Vancouver, BC – August 22, 2024 – Augurex Life Sciences Corp., a leader in biomarker-driven diagnostic solutions for the detection and management of autoimmune diseases, today announced its successful certification under the Medical Device Single Audit Program...
Veteran life sciences executive Mr. Neil Klompas to assume role of President and CEO
Augurex Life Sciences Corp. Names Healthcare Leader Neil Klompas to Succeed Co-Founder Dr. Norma Biln as President and CEO Veteran life sciences executive Mr. Neil Klompas to assume role of President and CEOCo-Founder and outgoing CEO Dr. Norma Biln to helm research...
Life Sciences BC Names Augurex 2024 Emerging Company of the Year
VANCOUVER, BC – Life Sciences BC (LSBC) is pleased to announce the recipients of the 26th Annual Life Sciences BC Awards presented by Farris. These awards recognize the exceptional achievements of individuals, companies, and organizations across British Columbia’s...
New Day Diagnostics Collaboration
Augurex and New Day Diagnostics Collaborate to Launch SPINEstat™, Revolutionizing Early Diagnosis and Management of Ankylosing Spondylitis Augurex and New Day Diagnostics Collaborate to Launch SPINEstat™, Revolutionizing Early Diagnosis and Management of Ankylosing...
Augurex has received $5M in funding from PacifiCan
Government of Canada invests almost $14 million to drive innovation and economic growth in Vancouver.Today, the Honourable Mary Ng, Minister of Export Promotion, International Trade and Economic Development on behalf of the Honourable Harjit S. Sajjan, Minister of...
Leading health publications are sharing the 14-3-3η blood test as part of the standard of care
Practical Pain Management highlights the 14-3-3η blood test The 14-3-3η blood test has been highlighted for earlier, more accurate diagnosis of rheumatoid arthritis by Practical Pain Management (PPM), a trusted publication providing evidence-based strategies for the...
Augurex and New Day Diagnostics Announce Launch of Anti-14-3-3eta Multiplex Analyte Specific Reagents; Enabling a First-In-Class Diagnostic Test for Axial Spondyloarthritis
Augurex launches Anti-14-3-3eta Multiplex Analyte Specific Reagents (ASRs), supporting the development of a first-in-class diagnostic test for axial spondyloarthritis (axSpA) by New Day Diagnostics. The new laboratory developed test, which uses Anti-14-3-3eta...
Augurex to Present Axial Spondyloarthritis Data and Exhibit at ACR Convergence 2024 in Washington, DC
Augurex will present new research on 14-3-3η auto-antibodies as a diagnostic marker for axial spondyloarthritis. Augurex will be exhibiting at booth #2540, showcasing its innovative diagnostic for rheumatoid arthritis and newly launched first-in-class diagnostic test...
Augurex to Present Research on Novel Diagnostic 14-3-3η Auto-Antibody Marker for Axial Spondyloarthritis at the Spondylo Congress in Ghent
Vancouver, Canada – August 20, 2024 – Augurex Life Sciences Corp. today announced that it will be presenting a scientific poster at the upcoming Spondylo Congress, taking place in Ghent, Belgium, from September 5th to 7th, 2024.Augurex’s poster, titled "Novel...
Augurex to Present Two Posters at ADLM 2024 in Chicago
Vancouver, Canada – July 26, 2024 – Augurex Life Sciences Corp. is pleased to announce that it will be presenting two posters at the upcoming Association for Diagnostic & Laboratory Medicine (ADLM 2024) in Chicago. The event will be held from July 28 to August 1,...
Augurex and Quidel at ACR
Augurex and Quidel are pleased to announce the launch of the JOINTstat® 14-3-3η RUO (research use only) ELISA. This new distribution arrangement will get 14-3-3η testing into the hands of more investigators worldwide, including key opinion leaders and pharmaceutical...
B.C.’s Most Influential Women 2018: Stem Stars
Working in STEM means that you’re innovative, you’re creative, you’re passionate, you’re clever, you’re whoever you want to be. We're so proud of our CEO Norma Biln being recognized by BC Business as a vital contributor to Women in Tech: [button...
Augurex Presenting at World Congress on Inflammation
At the 12th World Congress on Inflammation in Boston from August 8-12, Dr. Anthony Marotta will be co-chairing Symposium #29: Biomarkers in Inflammation: Focus on Rheumatoid Arthritis and will be delivering the following two presentations alongside presenter and...
JOIN OUR WEBINAR: JOINTstat™ – A New Blood Test for Rheumatoid Arthritis Diagnosis
Canadian Rheumatologist Webinar You are invited to: Introducing JOINTstat™ (14-3-3η): A New Biomechanistic Marker for the Early Diagnosis and Prognosis of Rheumatoid Arthritis Presenter: Walter P. Maksymowych, MD F.R.C.P.(C) Professor and Medical Scientists in the...
Home
Products
Science
About
News
Careers
Contact